Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Jennifer Domm"'
Autor:
Katherine A. Minson, Pinki Prasad, Susan Vear, Scott Borinstein, Richard Ho, Jennifer Domm, Haydar Frangoul
Publikováno v:
Case Reports in Hematology, Vol 2013 (2013)
Several cytogenetic abnormalities identified in patients with childhood acute lymphocytic leukemia (ALL) have been associated with a poor prognosis. There are several case reports in the literature describing t(17;19) in children with ALL. This trans
Externí odkaz:
https://doaj.org/article/6fca80804d0d4e49aa61a9a7ee0fe2cf
Autor:
Misty Evans, Susan Kelly, Lyndsay Molinari, Jennifer Domm, Clinton Carroll, Leigh Greer, Sandra Ward, Meghann McManus, Haydar Frangoul
Publikováno v:
Transplantation and Cellular Therapy. 29:S180
Autor:
Angela Yen, Damiano Rondelli, la Fuente Josu de, Amanda M. Li, Jennifer Domm, Montalembert Mariane de, Tony W. Ho, Donna A. Wall, Brenda K. Eustace, Juergen Foell, Sujit Sheth, Haydar Frangoul, Rupert Handgretinger, Akshay Sharma, Sandeep Soni, Antonis Kattamis, Andrew Kernytsky, Franco Locatelli, Stephan A. Grupp, M. Domenica Cappellini, Julie A. Lekstrom-Himes, Selim Corbacioglu, David Altshuler, Markus Y. Mapara, Yi-Shan Chen, Martin H. Steinberg
Transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) are severe monogenic diseases with severe and potentially life-threatening manifestations. BCL11A is a transcription factor that represses γ-globin expression and fetal hemoglo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::294f2984b8848005c8f160412c9178cd
https://hdl.handle.net/10807/228473
https://hdl.handle.net/10807/228473
Publikováno v:
Bone Marrow Transplantation. 53:647-650
Autor:
Leigh Greer, Darren Johnson, Julie Isbell, Haydar Frangoul, Katie Bruce, Tiffany Egan, Misty Evans, Carlos Bachier, Jennifer Domm, Minoo Battiwalla, Roy S Graham
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S218-S219
Background Plerixafor is used as an adjuvant to standard G-CSF mobilization to increases CD34+ cell mobilization and decreases the need for multiple days of collection. For patients with multiple myeloma (MM) and a collection goal of ≥5 × 10e6 CD3
Autor:
Heidi Chen, Mohamed Abdelhaleem, Soheil Meshinchi, Adam Gassas, Johann Hitzler, Jennifer Domm, Richard H. Ho, Haydar Frangoul, Jessica A. Pollard, Tal Schechter, Ann E. Woolfrey, Irina Zaidman
Publikováno v:
Biology of Blood and Marrow Transplantation. 21(1):172-175
FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) is a somatic mutation associated with poor outcome when treated with chemotherapy alone. In children, hematopoietic stem cell transplantation (HSCT) is recommended, but very limited
Autor:
Rainer Storb, David A. Margolis, K. Scott Baker, Brenda M. Sandmaier, Colleen Delaney, Julie-An Talano, Jennifer Domm, Haydar Frangoul, Kelsey Baker, Lauri Burroughs, Akiko Shimamura, Eneida R. Nemecek, Amy E. Geddis, H. Joachim Deeg, Ann E. Woolfrey
Hematopoietic cell transplantation (HCT) is effective in the treatment of inherited marrow failure disorders and other nonmalignant diseases. Conventional myeloablative conditioning regimens have been associated with high transplant-related mortality
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0c7d8127345f88cae12fa9aa76610fe
https://europepmc.org/articles/PMC5605451/
https://europepmc.org/articles/PMC5605451/
Autor:
Natasha B. Halasa, Benjamin R. Saville, John V. Williams, Jennifer Domm, Haydar Frangoul, Meng Xu, E. Kathryn Miller, Carolina Loria, Elizabeth Heitman
Publikováno v:
Pediatric Transplantation
Children with cancer and HSCT recipients are at high risk for common viral infections. We sought to define the viral etiology of ARI and identify risk factors. Nasal wash samples were collected from pediatric hematology-oncology patients and HSCT rec
Autor:
Julie Isbell, Leigh Greer, Carlos Bachier, Haydar Frangoul, Katie Bruce, Misty Evans, Darren Johnson, Jennifer Domm, Sandra Ward
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S203
Background Approximately 40-50% of HSCT are ABO incompatible and bone marrow (BM) products contain 25-35% of incompatible RBCs. RBC reduction can be performed using several different techniques including manual RBC sedimentation using hydroxyethyl st
Autor:
Jennifer Domm, Julie Isbell, Katie Bruce, Haydar Frangoul, Misty Evans, Darren Johnson, Leigh Greer, Ayad Ahmed Hussein
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S120
Introduction Allogeneic HSCT (alloHSCT) offers a potential cure for patients with AML; however, 40% of AML patients receiving alloHSCT will experience relapsed disease. Second alloHSCT can offer the best long-term survival but is associated with sign